INS and COVID-19: It remains to be seen if inpatient strict BG control has a mortality benefit in COVID-19 hyperglycemic patients with or without T2D, given the evidence that insulin infusion is associated with a lower risk of severe COVID-19 [24] and that tight glycemic control could improve hospital outcomes in patients with acute coronary events [25,26].